Table 4.
Pooled RR of adverse events in FD patients receiving acotiamide versus placebo by Mantel-Haenszel fixed-effect model.
| Groups | Number of trials [reference] | Number of patients | RR; 95% CI | P value | Test of heterogeneity | |
|---|---|---|---|---|---|---|
| P value | I 2 | |||||
| Serum prolactin increaseda | 4 [11, 16, 25] | 1709 | 1.59; 0.79–3.21 | 0.190 | 0.120 | 40% |
| Alanine aminotransferase increased | 4 [11, 16, 25] | 1709 | 1.42; 0.82–2.47 | 0.210 | 0.710 | 0% |
| Triglycerides increased | 3 [16, 25] | 1667 | 0.89; 0.69–1.14 | 0.360 | 0.810 | 0% |
| γ-glutamyltransferase increased | 3 [16, 25] | 1667 | 1.01; 0.66–1.54 | 0.970 | 0.630 | 0% |
| White blood cell count increased | 1 [25] | 892 | 0.65; 0.34–1.27 | 0.210 | NA | NA |
| Serum bilirubin increased | 1 [25] | 892 | 1.04; 0.55–1.95 | 0.910 | NA | NA |
| Constipation | 2 [16] | 775 | 0.99; 0.34–2.92 | 0.980 | 0.620 | 0% |
| Diarrhoea | 3 [16, 25] | 1667 | 1.34; 0.81–2.23 | 0.250 | 0.860 | 0% |
| Nasopharyngitis | 1 [25] | 892 | 0.93; 0.61–1.42 | 0.750 | NA | NA |
aMantel-Haenszel random-effects model.
CI, confidential interval; FD, functional dyspepsia; NA, not applicable; and RR, risk ratio.